Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis

Autor: Lefort, M, Sharmin, S, Andersen, J B, Vukusic, S, Casey, R, Debouverie, M, Edan, G, Ciron, J, Ruet, A, De Sèze, J, Maillart, E, Zephir, H, Labauge, P, Defer, G, Lebrun-Frenay, C, Moreau, T, Berger, E, Clavelou, P, Pelletier, J, Stankoff, B, Gout, O, Thouvenot, E, Heinzlef, O, Al-Khedr, A, Bourre, B, Casez, O, Cabre, P, Montcuquet, A, Wahab, A, Camdessanché, J P, Maurousset, A, Ben Nasr, H, Hankiewicz, K, Pottier, C, Maubeuge, N, Dimitri-Boulos, D, Nifle, C, Laplaud, D A, Horakova, D, Havrdova, E K, Alroughani, R, Izquierdo, G, Eichau, S, Ozakbas, S, Patti, F, Onofrj, M, Lugaresi, A, Terzi, M, Grammond, P, Grand'Maison, F, Yamout, B, Prat, A, Girard, M, Duquette, P, Boz, C, Trojano, M, McCombe, P, Slee, M, Lechner-Scott, J, Turkoglu, R, Sola, P, Ferraro, D, Granella, F, Shaygannejad, V, Prevost, J, Maimone, D, Skibina, O, Buzzard, K, Van der Walt, A, Karabudak, R, Van Wijmeersch, B, Csepany, T, Spitaleri, D, Vucic, S, Koch-Henriksen, N, Sellebjerg, F, Soerensen, P S, Hilt Christensen, C. C., Rasmussen, P V, Jensen, M B, Frederiksen, J L, Bramow, S, Mathiesen, H K, Schreiber, K I, Butzkueven, H, Magyari, M, Kalincik, T, Leray, E

Publikováno v: Lefort, M, Sharmin, S, Andersen, J B, Vukusic, S, Casey, R, Debouverie, M, Edan, G, Ciron, J, Ruet, A, De Sèze, J, Maillart, E, Zephir, H, Labauge, P, Defer, G, Lebrun-Frenay, C, Moreau, T, Berger, E, Clavelou, P, Pelletier, J, Stankoff, B, Gout, O, Thouvenot, E, Heinzlef, O, Al-Khedr, A, Bourre, B, Casez, O, Cabre, P, Montcuquet, A, Wahab, A, Camdessanché, J P, Maurousset, A, Ben Nasr, H, Hankiewicz, K, Pottier, C, Maubeuge, N, Dimitri-Boulos, D, Nifle, C, Laplaud, D A, Horakova, D, Havrdova, E K, Alroughani, R, Izquierdo, G, Eichau, S, Ozakbas, S, Patti, F, Onofrj, M, Lugaresi, A, Terzi, M, Grammond, P, Grand’Maison, F, Yamout, B, Prat, A, Girard, M, Duquette, P, Boz, C, Trojano, M, McCombe, P, Slee, M, Lechner-Scott, J, Turkoglu, R, Sola, P, Ferraro, D, Granella, F, Shaygannejad, V, Prevost, J, Maimone, D, Skibina, O, Buzzard, K, Van der Walt, A, Karabudak, R, Van Wijmeersch, B, Csepany, T, Spitaleri, D, Vucic, S, Koch-Henriksen, N, Sellebjerg, F, Soerensen, P S, Hilt Christensen, C C, Rasmussen, P V, Jensen, M B, Frederiksen, J L, Bramow, S, Mathiesen, H K, Schreiber, K I, Butzkueven, H, Magyari, M, Kalincik, T & Leray, E 2022, ' Impact of methodological choices in comparative effectiveness studies : application in natalizumab versus fingolimod comparison among patients with multiple sclerosis ', BMC Medical Research Methodology, vol. 22, no. 1, 155 . https://doi.org/10.1186/s12874-022-01623-8
BMC Medical Research Methodology
BMC Medical Research Methodology, 2022, 22 (1), pp.155. ⟨10.1186/s12874-022-01623-8⟩
BMC Medical Research Methodology, BioMed Central, 2022, 22 (1), pp.155. ⟨10.1186/s12874-022-01623-8⟩
Lefort, M, Sharmin, S, Andersen, J B, Vukusic, S, Casey, R, Debouverie, M, Edan, G, Ciron, J, Ruet, A, De Sèze, J, Maillart, E, Zephir, H, Labauge, P, Defer, G, Lebrun-Frenay, C, Moreau, T, Berger, E, Clavelou, P, Pelletier, J, Stankoff, B, Gout, O, Thouvenot, E, Heinzlef, O, Al-Khedr, A, Bourre, B, Casez, O, Cabre, P, Montcuquet, A, Wahab, A, Camdessanché, J P, Maurousset, A, Ben Nasr, H, Hankiewicz, K, Pottier, C, Maubeuge, N, Dimitri-Boulos, D, Nifle, C, Laplaud, D A, Horakova, D, Havrdova, E K, Alroughani, R, Izquierdo, G, Eichau, S, Ozakbas, S, Patti, F, Onofrj, M, Lugaresi, A, Terzi, M, Grammond, P, Grand'Maison, F, Yamout, B, Prat, A, Girard, M, Duquette, P, Boz, C, Trojano, M, McCombe, P, Slee, M, Lechner-Scott, J, Turkoglu, R, Sola, P, Ferraro, D, Granella, F, Shaygannejad, V, Prevost, J, Maimone, D, Skibina, O, Buzzard, K, Van der Walt, A, Karabudak, R, Van Wijmeersch, B, Csepany, T, Spitaleri, D, Vucic, S, Koch-Henriksen, N, Sellebjerg, F, Soerensen, P S, Hilt Christensen, C C, Rasmussen, P V, Jensen, M B, Frederiksen, J L, Bramow, S, Mathiesen, H K, Schreiber, K I, Butzkueven, H, Magyari, M, Kalincik, T & Leray, E 2022, ' Impact of methodological choices in comparative effectiveness studies : application in natalizumab versus fingolimod comparison among patients with multiple sclerosis ', BMC Medical Research Methodology, vol. 22, no. 1, 155 . https://doi.org/10.1186/s12874-022-01623-8

Background Natalizumab and fingolimod are used as high-efficacy treatments in relapsing-remitting multiple sclerosis. Several observational studies comparing these two drugs have shown variable results, using different methods to control treatment in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b76c9aa3b89340f07462e048e392906e
https://avesis.deu.edu.tr/publication/details/fef052b9-7e13-4a9f-b86e-a900c3dd0924/oai

BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS

Autor: Cohen, Mikael, Mondot, Lydiane, Bucciarelli, Florence, Pignolet, Béatrice, Laplaud, David-Axel, Wiertlewski, Sandrine, Brochet, Bruno, Ruet, Aurélie, Defer, Gilles, Derache, Nathalie, Vermersch, Patrick, Zephir, Hélène, Debouverie, Marc, Mathey, Guillaume, Berger, Eric, Cappé, Chrystelle, Labauge, Pierre, Carra, Clarisse, de Seze, Jérôme, Bigaut, Kevin, Brassat, David, Lebrun-Frenay, Christine

Publikováno v: Multiple Sclerosis Journal
Multiple Sclerosis Journal, 2020, 27 (10), pp.1556-1563. ⟨10.1177/1352458520969145⟩

International audience; Background: There are few head-to-head studies to compare highly active treatments in multiple sclerosis (MS) Objective: The aim of this study was to compare the effectiveness between natalizumab (NTZ) and fingolimod (FTY) in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______4254::79aefeb53e1723664db3c0bdd9895ceb
https://ut3-toulouseinp.hal.science/hal-03166333

Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis

Autor: Wilkins, Alastair, Slee, Mark, TERZİ, MURAT, Grand'Maison, Francois, Ferraro, Diana, Sola, Patrizia, Van Pesch, Vincent, McCombe, Pamela, Hupperts, Raymond, Alroughani, Raed, Grammond, Pierre, Bergamaschi, Roberto, Lugaresi, Alessandra, Shaygannejad, Vahid, Pucci, Eugenio, Granella, Franco, Jokubaitis, Vilija, Pearson, Owen R., Ziemssen, Tjalf, Hutchinson, Michael, McGuigan, Christopher, Butzkueven, Helmut, Kalincik, Tomas, Onofrj, Marco, Trojano, Maria, Duquette, Pierre, Girard, Marc, Prat, Alexandre, Izquierdo, Guillermo, Havrdova, Eva, Horakova, Dana, Zwanikken, Cees, Soysal, Aysun, Yamout, Bassem, Piroska, Imre, McDonnell, Gavin, Moore, Fraser, Butler, Ernest, De Luca, Giovanna, Di Tommaso, Valeria, Travaglini, Daniela, Pietrolongo, Erika, di Ioia, Maria, Farina, Deborah, Mancinelli, Luca, Hodgkinson, Suzanne, Oreja-Guevara, Celia, BOZ, CAVİT, Prevost, Julie, Olascoaga, Javier, Van Wijmeersch, Bart, Barnett, Michael, Verheul, Freek, Rojas, Juan Ingacio, Spitaleri, Daniele, Rio, Maria Edite, Taylor, Bruce, Luis Sanchez-Menoyo, Jose, Ramo-Tello, Cristina, Solaro, Claudio, Csepany, Tunde, Iuliano, Gerardo, Skibina, Olga, Petersen, Thor, Bolanos, Ricardo Fernandez, Sidhom, Youssef, Riadh, Riadh, Vucic, Steve, Macdonell, Richard, Sempere, Angel Perez, Simo, Magdolna, Kister, Ilya, Shuey, Neil, Radek, Radek, Dominguez, Jose Andres, Pia Amato, Maria, Saladino, Maria Laura, Kermode, Allan, Brown, J. William L., Coles, Alasdair, Lechner-Scott, Jeannette, Willis, Mark, Rice, Claire, Scolding, Neil, Flechter, Schlomo, Harding, Katharine, Jones, Joanne, Robertson, Neil, Hughes, Stella, ÖZAKBAŞ, SERKAN

Publikováno v: JAMA, Vol. 321, no. 2, p. 175-187 (2019)
JAMA-Journal of the American Medical Association, 321(2), 175-187. American Medical Association
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Brown, J W L, Coles, A, Horakova, D, Havrdova, E, Izquierdo, G, Prat, A, Girard, M, Duquette, P, Trojano, M, Lugaresi, A, Bergamaschi, R, Grammond, P, Alroughani, R, Hupperts, R, McCombe, P, Van Pesch, V, Sola, P, Ferraro, D, Grand'Maison, F, Terzi, M, Lechner-Scott, J, Flechter, S, Slee, M, Shaygannejad, V, Pucci, E, Granella, F, Jokubaitis, V, Willis, M, Rice, C, Scolding, N, Wilkins, A, Pearson, O R, Ziemssen, T, Hutchinson, M, Harding, K, Jones, J, McGuigan, C, Butzkueven, H, Kalincik, T & Robertson, N 2019, ' Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis ', JAMA-Journal of the American Medical Association, vol. 321, no. 2, pp. 175-187 . https://doi.org/10.1001/jama.2018.20588

none 40 si his study was financially supported by National Health and Medical Research Council of Australia (fellowships 1140766 and 1080518, project grants 1129189 and 1083539), the University of Melbourne (Faculty of Medicine, Dentistry and Health

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e679d8c2a4a1e815cbd46fc7a4b7fa0
https://hdl.handle.net/10668/13424

Fingolimod protects against neonatal white matter damage and long-term cognitive deficits caused by hyperoxia

Autor: Ursula Felderhoff-Müser, Wiebke Hansen, Ivo Bendix, Josephine Herz, Marco Sifringer, Katharina Lumpe, Karina Kempe, Ralf Herrmann, Martin Hadamitzky, Xinlin Hou, Yohan van de Looij, Meray Serdar, Stéphane Sizonenko, Barbara S. Reinboth, Rolf Heumann

Publikováno v: Brain, behavior, and immunity, Vol. 52 (2016) pp. 106-19

Cerebral white matter injury is a leading cause of adverse neurodevelopmental outcome in prematurely born infants involving cognitive deficits in later life. Despite increasing knowledge about the pathophysiology of perinatal brain injury, therapeuti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::107efda10ac14301a02fe7283fc9f3ef
https://www.ncbi.nlm.nih.gov/pubmed/26456693